Ascentage Pharma Group Internat (AAPG:NASDAQ) closed at $15.44 on October 23, 2026, up 3.49% on the day. The stock trades 56.5% below its 52-week high of $35.46 and 6.8% above its 52-week low of $14.46. Over the past year, it lost 56.5%. Ascentage Pharma Group Internat is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, AAPG closed higher on 117 days (46%). Its best day was March 23, 2026 (+16.80%) and its worst was March 20, 2026 (-13.29%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 5 times.
Ascentage Pharma Group is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Our lead assets, olverembatinib and lisaftoclax, have global potential to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. We are the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. We have eleven completed or ongoing U.S. and/or international registrational trials, including two that are FDA-regulated, for our five key clinical-stage assets.
Find more stocks like AAPG with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.